Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “AK112”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06601335
What this trial is testing

AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Akeso 510
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06936644
What this trial is testing

A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

Who this might be right for
KRAS G12C Lung Cancer
Shanghai Chest Hospital 39
Testing effectiveness (Phase 2)Ended earlyNCT05636267
What this trial is testing

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Who this might be right for
NSCLC
Akeso 59
Testing effectiveness (Phase 2)Looking for participantsNCT06444009
What this trial is testing

A Phase II Study of Neoadjuvant Immunotherapy in Combination With Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Lei Liu 90
Not applicableNot Yet RecruitingNCT07440212
What this trial is testing

Clinical Study on Noninvasive Evaluation of Ivonescimab Antibody Distribution and Expression in Esophageal Cancer Patients by 89Zr-AK112 PET Imaging

Who this might be right for
Esophagus Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 50
Testing effectiveness (Phase 2)Study completedNCT04870177
What this trial is testing

Study of AK112 in the Treatment of Advanced Gynecological Tumors

Who this might be right for
Gynecologic CancerCancer MetastaticOvarian Neoplasms+2 more
Akeso 53
Testing effectiveness (Phase 2)Looking for participantsNCT06489197
What this trial is testing

AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients

Who this might be right for
ESCCAdvanced Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07244978
What this trial is testing

Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal Squamous Cell CarcinomaNeoadjuvant Therapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 49
Testing effectiveness (Phase 2)UnknownNCT06391008
What this trial is testing

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Who this might be right for
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT05229497
What this trial is testing

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Who this might be right for
Advanced Malignant Tumors
Akeso 154
Not applicableNot Yet RecruitingNCT06766591
What this trial is testing

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

Who this might be right for
NSCLCChemotherapyLeptomeningeal Metastases+2 more
Jiangsu Province Nanjing Brain Hospital 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07489703
What this trial is testing

SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05227664
What this trial is testing

AK117/AK112 in Metastatic Triple-Negative Breast Cancer

Who this might be right for
Metastatic Triple-negative Breast CancerLocally Advanced Triple-negative Breast Cancer
Akeso 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07086326
What this trial is testing

A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

Who this might be right for
NSCLCNeoadjuvant TherapyImmunotherapy+2 more
Yang Fan, MD 164
Testing effectiveness (Phase 2)Looking for participantsNCT07162714
What this trial is testing

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

Who this might be right for
Rectal CancerRadiationAK112
Zhejiang Cancer Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07021950
What this trial is testing

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerIvonescimab
Sun Yat-sen University 130
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07357220
What this trial is testing

AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases

Who this might be right for
Colorectal Cancer With Hepatic Metastases
Akeso 72
Testing effectiveness (Phase 2)Looking for participantsNCT06769295
What this trial is testing

A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

Who this might be right for
Lung Cancer, Non-Small Cell
Sichuan University 28
Large-scale testing (Phase 3)Looking for participantsNCT06767527
What this trial is testing

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer (TNBC)
Akeso 416
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06196814
What this trial is testing

AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC

Who this might be right for
Efficacy
Hunan Province Tumor Hospital 150
Next Page